Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials von Spiegelberg, Linda, Houben, Ruud, Niemans, Raymon, de Ruysscher, Dirk, Yaromina, Ala, Theys, Jan, Guise, Christopher P., Smaill, Jeffrey B., Patterson, Adam V., Lambin, Philippe, Dubois, Ludwig J.

Volltext

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302 von Meng, Fanying, Evans, James W, Bhupathi, Deepthi, Banica, Monica, Lan, Leslie, Lorente, Gustavo, Duan, Jian-Xin, Cai, Xiaohong, Mowday, Alexandra M, Guise, Christopher P, Maroz, Andrej, Anderson, Robert F, Patterson, Adam V, Stachelek, Gregory C, Glazer, Peter M, Matteucci, Mark D, Hart, Charles P

Volltext

FSL-61 is a 6-nitroquinolone fluorogenic probe for one-electron reductases in hypoxic cells von Su, Jiechuang, Guise, Christopher P, Wilson, William R

Volltext

Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy von Copp, Janine N., Mowday, Alexandra M., Williams, Elsie M., Guise, Christopher P., Ashoorzadeh, Amir, Sharrock, Abigail V., Flanagan, Jack U., Smaill, Jeff B., Patterson, Adam V., Ackerley, David F.

Volltext

The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3 von GUISE, Christopher P, ABBATTISTA, Maria R, DONATE, Fernando, WILSON, William R, PATTERSON, Adam V, SINGLETON, Rachelle S, HOLFORD, Samuel D, CONNOLLY, Joanna, DACHS, Gabi U, FOX, Stephen B, POLLOCK, Robert, HARVEY, Justin, GUILFORD, Parry

Volltext

Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress von Mowday, Alexandra M, Guise, Christopher P, Ackerley, David F, Minton, Nigel P, Lambin, Philippe, Dubois, Ludwig J, Theys, Jan, Smaill, Jeff B, Patterson, Adam V

Volltext

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506 von van der Wiel, Alexander M A, Jackson-Patel, Victoria, Niemans, Raymon, Yaromina, Ala, Liu, Emily, Marcus, Damiënne, Mowday, Alexandra M, Lieuwes, Natasja G, Biemans, Rianne, Lin, Xiaojing, Fu, Zhe, Kumara, Sisira, Jochems, Arthur, Ashoorzadeh, Amir, Anderson, Robert F, Hicks, Kevin O, Bull, Matthew R, Abbattista, Maria R, Guise, Christopher P, Deschoemaeker, Sofie, Thiolloy, Sophie, Heyerick, Arne, Solivio, Morwena J, Balbo, Silvia, Smaill, Jeff B, Theys, Jan, Dubois, Ludwig J, Patterson, Adam V, Lambin, Philippe

Volltext

Design and Biological Evaluation of Piperazine-Bearing Nitrobenzamide Hypoxia/GDEPT Prodrugs: The Discovery of CP-506 von Ashoorzadeh, Amir, Mowday, Alexandra M, Abbattista, Maria R, Guise, Christopher P, Bull, Matthew R, Silva, Shevan, Patterson, Adam V, Smaill, Jeff B

Volltext

2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors von Li, Xueqiang, Guise, Christopher P., Taghipouran, Rana, Yosaatmadja, Yuliana, Ashoorzadeh, Amir, Paik, Woo-Kyong, Squire, Christopher J., Jiang, Shuang, Luo, Jinfeng, Xu, Yong, Tu, Zheng-Chao, Lu, Xiaoyun, Ren, Xiaomei, Patterson, Adam V., Smaill, Jeff B., Ding, Ke

Volltext

Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours von Mowday, Alexandra M., Dubois, Ludwig J., Kubiak, Aleksandra M., Chan-Hyams, Jasmine V. E., Guise, Christopher P., Ashoorzadeh, Amir, Lambin, Philippe, Ackerley, David F., Smaill, Jeff B., Minton, Nigel P., Theys, Jan, Patterson, Adam V.

Volltext

Engineering Escherichia coli NfsB To Activate a Hypoxia-Resistant Analogue of the PET Probe EF5 To Enable Non-Invasive Imaging during Enzyme Prodrug Therapy von Williams, Elsie M, Rich, Michelle H, Mowday, Alexandra M, Ashoorzadeh, Amir, Copp, Janine N, Guise, Christopher P, Anderson, Robert F, Flanagan, Jack U, Smaill, Jeff B, Patterson, Adam V, Ackerley, David F

Volltext

A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells von Jamieson, Stephen M.F., Gu, Yongchuan, Manesh, Donya Moradi, El-Hoss, Jad, Jing, Duohui, MacKenzie, Karen L., Guise, Christopher P., Foehrenbacher, Annika, Pullen, Susan M., Benito, Juliana, Smaill, Jeffrey B., Patterson, Adam V., Mulaw, Medhanie A., Konopleva, Marina, Bohlander, Stefan K., Lock, Richard B., Wilson, William R.

Volltext

2‑Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors von Mo, Cheng, Zhang, Zhang, Guise, Christopher P, Li, Xueqiang, Luo, Jinfeng, Tu, Zhengchao, Xu, Yong, Patterson, Adam V, Smaill, Jeff B, Ren, Xiaomei, Lu, Xiaoyun, Ding, Ke

Volltext

Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3 von Abbattista, Maria R, Ashoorzadeh, Amir, Guise, Christopher P, Mowday, Alexandra M, Mittra, Rituparna, Silva, Shevan, Hicks, Kevin O, Bull, Matthew R, Jackson-Patel, Victoria, Lin, Xiaojing, Prosser, Gareth A, Lambie, Neil K, Dachs, Gabi U, Ackerley, David F, Smaill, Jeff B, Patterson, Adam V

Volltext

Prototyping kinase inhibitor-cytotoxin anticancer mutual prodrugs activated by tumour hypoxia: A chemical proof of concept study von Sansom, Geraud N., Kirk, Nicholas S., Guise, Christopher P., Anderson, Robert F., Smaill, Jeff B., Patterson, Adam V., Kelso, Michael J.

Volltext

Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications von Ashoorzadeh, Amir, Mowday, Alexandra M, Guise, Christopher P, Silva, Shevan, Bull, Matthew R, Abbattista, Maria R, Copp, Janine N, Williams, Elsie M, Ackerley, David F, Patterson, Adam V, Smaill, Jeff B

Volltext

Diflavin Oxidoreductases Activate the Bioreductive Prodrug PR-104A under Hypoxia von Guise, Christopher P., Abbattista, Maria R., Tipparaju, Smitha R., Lambie, Neil K., Su, Jiechuang, Li, Dan, Wilson, William R., Dachs, Gabi U., Patterson, Adam V.

Volltext

Zinc Finger Nuclease Knock-out of NADPH:Cytochrome P450 Oxidoreductase (POR) in Human Tumor Cell Lines Demonstrates That Hypoxia-activated Prodrugs Differ in POR Dependence von Su, Jiechuang, Gu, Yongchuan, Pruijn, Frederik B., Smaill, Jeff B., Patterson, Adam V., Guise, Christopher P., Wilson, William R.

Volltext

Synthesis and cytotoxicity of pyranonaphthoquinone natural product analogues under bioreductive conditions von Heapy, Amanda M., Patterson, Adam V., Smaill, Jeff B., Jamieson, Stephen M.F., Guise, Christopher P., Sperry, Jonathan, Hume, Paul A., Rathwell, Kris, Brimble, Margaret A.

Volltext

Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy von Mowday, Alexandra M., Ashoorzadeh, Amir, Williams, Elsie M., Copp, Janine N., Silva, Shevan, Bull, Matthew R., Abbattista, Maria R., Anderson, Robert F., Flanagan, Jack U., Guise, Christopher P., Ackerley, David F., Smaill, Jeff B., Patterson, Adam V.

Volltext